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The BRCA1 gene product helps to maintain genomic integrity through its participation in the cellular response to DNA damage:
specifically, the repair of double-stranded DNA breaks. An impaired cellular response to DNA damage is a plausible mechanism
whereby BRCA1 mutation carriers are at increased risk of breast cancer. Hence, an individual’s capacity to repair DNA may serve as a
useful biomarker of breast cancer risk. The overall aim of the current study was to identify a biomarker of DNA repair capacity that
could distinguish between BRCA1 mutation carriers and non-carriers. DNA repair capacity was assessed using three validated assays:
the single-cell alkaline gel electrophoresis (comet) assay, the micronucleus test, and the enumeration of g-H2AX nuclear foci. DNA
repair capacity of peripheral blood lymphocytes from 25 cancer-free female heterozygous BRCA1 mutation carriers and 25 non-
carrier controls was assessed at baseline and following cell exposure to g – irradiation (2Gy). We found no significant differences in
the mean tail moment, in the number of micronuclei or in the number of g-H2AX nuclear foci between the carriers and non-carriers
at baseline, and following g-irradiation. These data suggest that these assays are not likely to be useful in the identification of women
at a high risk for breast cancer.
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The inheritance of a deleterious mutation in the breast cancer
susceptibility gene, BRCA1, has been associated with a lifetime risk
of breast cancer of between 45 and 87% (Ford et al, 1998; Antoniou
et al, 2003). Genetic, reproductive, and environmental factors have
all been suggested to influence breast cancer risk in BRCA1
mutation carriers (reviewed in Narod and Offit (2005)). The use of
breast cancer as an endpoint to evaluate the protective role of
potential modifying factors is not always feasible. Thus, there is a
need to ascertain biomarkers of cancer susceptibility in these
women. In turn, the identification of a valid biomarker of breast
cancer risk would allow us to identify mutation carriers and help
improve our ability to target, and to evaluate the effect of both
dietary and lifestyle alterations, as well as, medical diagnostic and
therapeutic interventions on breast cancer risk.
The BRCA1 protein plays a vital role in maintaining genomic
stability because of its key role in the repair of double-stranded
DNA breaks by homologous recombination (reviewed in Welcsh
et al (2000)). If double-stranded DNA breaks are left unrepaired,
or are repaired inaccurately, aberrant chromosome breaks,
deletions, and translocations may accumulate. Thus, an impaired
cellular response to DNA damage appears to be a plausible
mechanism whereby BRCA1 mutation carriers are at an increased
risk of breast cancer (Scott, 2004). Hence, the evaluation of an
individual’s capacity to repair DNA may serve as a biomarker of
breast cancer risk in carriers of these mutations.
Two previous studies have shown higher levels of chromosomal
aberrations and chromosomal breaks among women with a BRCA1
mutation compared with non-carrier controls (Kowalska et al,
2005; Kote-Jarai et al, 2006); however, these cytogenetic assays are
laborious and expensive. The aim of the current paper was to
elucidate a relatively simple and inexpensive biomarker of breast
cancer susceptibility. We compared the DNA repair capacity of
BRCA1 mutation carriers and non-carriers using three previously
validated assays, the single-cell alkaline gel electrophoresis (comet)
assay, the micronucleus test, and g-H2AX staining, to determine
which, if any of these tests, would be able to predict the presence of
an inherited BRCA1 mutation.
MATERIALS AND METHODS
Subjects and study design
Eligible subjects were healthy females with no prior history of
breast or other cancers and were between the ages of 20–60 years.
We included 25 healthy BRCA1 mutation carriers and 25 healthy
mutation-negative females as controls. The controls were women
from the same families as the cases; that is a mutation had been
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sidentified in the family but they did not carry the family mutation.
Potential subjects were identified from two participating centres:
the Centre for Research in Women’s Health, Toronto, Ontario and
the London Health Sciences Centre, London, Ontario. Women were
invited to participate in the study by letter. Women were excluded
if they were pregnant or were suffering from a serious illness. The
majority of women who were approached agreed to participate.
The reasons given for declining our invitation included (1) travel
time to our clinic in downtown Toronto (many individuals live
outside the Greater Toronto Area), (2) dealing with other family
matters, (3) not interested, or (4) lost to follow-up.
Data collection
Participants completed three questionnaires before their visit to
the clinic. These included a diet history questionnaire (a food
frequency questionnaire that was developed by staff at the Risk
Factor Monitoring and Methods Branch at the National Cancer
Institute and reflects Canadian food availability and food
fortification practices) (Csizmadi et al, 2006), a ‘follow-up
questionnaire for a study of breast and ovarian cancer in high-
risk families’ with questions directed at reproductive histories,
prophylactic surgery, use of exogenous estrogens, and other
lifestyle factors, and a shorter ‘research questionnaire for a study
of genetic and non-genetic factors associated with breast cancer
risk in high-risk women’ that asked questions regarding use of
dietary supplements and physical activity.
At an on-site visit, biological samples were collected from all the
eligible participants, and were processed and stored for further
analyses. These included fasting blood samples, toenail clippings,
and urine samples. Standardised procedures were used to obtain
various anthropometric measurements (weight, waist, and hip
circumference, height).
Measurement of DNA repair capacity
The comet assay, micronucleus test and analysis of g-H2AX
nuclear foci were performed using lymphocytes extracted from
freshly collected blood. The assays were performed in the
laboratory of Dr Katherine Vallis at the Ontario Cancer Institute,
Princess Margaret Hospital, Toronto, Ontario.
Lymphocyte isolation and culture Five millilitres (ml) of blood
were collected from female heterozygous BRCA1 mutation carriers
and non-carrier controls by venipuncture into a heparin tube
(1unitml
 1) and kept on ice before being added into 25ml of
ice-cold Rosewell Park Memorial Institute medium (RPMI) 1640
medium supplemented with 2% foetal bovine serum (FBS). Twenty
ml of Ficoll was added to the bottom of the blood-RPMI cell
culture media. After centrifugation at 1200r.p.m. for 15mins at
41C, lymphocytes were collected from the layer between the RPMI
medium and Ficoll.
Single cell gel electrophoresis (comet) assay Lymphocytes were
either not irradiated (controls) or treated with 2Gy of g irradiation
(
137Cs g rays, dose rate of 1.07Gymin
 1) and placed on ice for no
recovery or allowed to recover for 1h at 371C. The irradiated cells
were then mixed with 100ml of 0.5% low melting agarose (melted
and kept warm at 421C in phosphate-buffered saline (PBS)) before
being loaded onto the slides pre-coated with 1% of agarose.
The DNA damage and repair were determined by the alkaline
comet assay as per standard protocols (Singh et al, 1988; Green
et al, 1992). All procedures preceding electrophoresis were carried
out on ice to prevent DNA repair except when samples were
deliberately set aside to allow for repair. Data were analysed using
a Zeiss fluorescence microscope with a  20 objective and image-
analysis software, Komet 5.0 (Kinetics Imaging Ltd., Liverpool,
UK). A minimum of 50 cells per slide were analysed. The tail
moment was calculated by the distance between the centre of mass
of the tail and the centre of mass of the head multiplied by the
percentage of DNA in the tail (Olive et al, 1990). An increase in the
tail moment provides evidence of an increased number of cellular
DNA strand breaks.
Micronucleus test Lymphocytes were stimulated with phytohae-
magglutinin (PHAP) (Sigma, 10mgml
 1 final) and were allowed to
grow for 20h in 10ml of RPMI with 10% FBS, 371C and 5% CO2.
Twenty hours after treatment with PHAP, cells were not irradiated
(controls) or irradiated with 2Gy (
137Cs g rays, dose rate of
1.07Gymin
 1). Forty-four hours after PHAP stimulation, cytocha-
lasin B (Sigma) was added to the cell culture (to a final
concentration of 4.5mgml
 1) to inhibit cytokinesis (cytoplasmic
division) without interfering with nuclear division. Thus, cyto-
chalasin B-treated cells become binucleated at the first cell
division. Sixty-eight hours after PHAP treatment, cells were
collected by centrifugation, treated with hypotonic solution
(70mM KCl), fixed with methanol/acetic acid (9:1), and stained
with 0.01% acridine orange (Sigma: Sigma-Aldrich Canada Ltd.,
Oakville, ON, Canada).
A fluorescent microscope was used to score micronuclei. The
results were recorded as the number of micronuclei per 1000
binucleated cells. The micronuclei were scored as positive if they
were distinguishable from the two main nuclei, if they were less
than one third the size of the main nuclei, and if they had similar
staining intensities to the main nuclei. Cells with irregularly
shaped nuclei, more than two nuclei, and those with nuclei of
different sizes in a single cell were not scored (Khan et al, 1998).
The number of micronuclei per binucleated cell was scored to
provide a measure of chromosome breakage (Fenech, 2000). A
minimum of 200 cells per slide were scored.
Immunohistochemistry for g-H2AX detection Lymphocytes were
not irradiated (controls) or g-irradiated (2Gy). After incubation at
371C for 30min and 3h, cells were spun down onto microscope
slides using a cytocentrifuge (Cytospin, Shandon; Thermo Fisher
Scientific, Waltham, MA, USA) 7min at 1200r.p.m.). The cells
were fixed by dipping the slides into 2% paraformaldehyde in
PBSþ0.5% Triton X-100, pH 8.2, 15min at room temperature
(Reitsema et al, 2004; Al Rashid et al, 2005). The primary antibody,
anti-phospho-H2AX (mouse monoclonal clone JBW301, Upstate,
Millipore Corp, Billerica, MA, USA’ – Note that Upstate has been
taken over by Millipore) was 1:500 diluted in filtered 3% bovine
serum albumin in PBS, and incubated overnight at 41C. After the
secondary antibody application, lymphocyte nucleus staining was
performed by incubating cells with 0.1mgml
 1 diaminophenyl
indole (DAPI) for 10min at room temperature. Wide-field
fluorescence images were captured using a Zeiss Axioskop
microscope with the  100 objective, filter sets for fluorescein
isothiocyanate and DAPI, and a Retiga CCD camera (QIMAGING,
British Columbia, Canada). Northern Eclipse (EMPIX, Mississauga,
Canada) software was used to acquire 8-bit images from which at
least 50 cells per slide were scored. One g-H2AX focus has been
shown to be equivalent to one DSB and is made up of 100’s–1000’s
of g-H2AX molecules (Pilch et al, 2003).
Statistical analysis
Descriptives The Student’s t-test was used to compare normally
distributed continuous variables between BRCA1 mutation carriers
and the non-carrier control subjects. The w
2 test was used to test
for categorical differences.
Multivariate analysis The primary objective of this study was to
examine whether any of the three assays could distinguish between
BRCA1 mutation carriers and non-carriers. To do so, unadjusted
and adjusted values were compared between the two groups of
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swomen. Differences in the mean DNA repair capacity between
BRCA1 mutation carriers and the non-carrier control subjects were
compared using the Student’s t-test. Multivariate linear regression
analysis was performed on the three markers of DNA repair
capacity treated as continuous dependent variables, and adjusting
for the potential confounding effects of age (continuous), body
mass index (kgm
 2), current smoker (yes/no), total drinks of
alcohol (continuous), total hours of physical activity per week
(continuous), and total caloric intake (kcal) (Berwick and Vineis,
2000; Palli et al, 2003).
Percentage of radiosensitive women For each of the three assays,
we estimated the number of radiosensitive individuals. An
arbitrary cut-off was based on the 90th percentile of the non-
carrier population (i.e. assumes that 10% of the population is
sensitive) (data not shown). The Fisher’s exact test was used to test
for differences in the percentage (%) of radiosensitive individuals
between BRCA1 mutation carriers and non-carriers.
All statistical tests were two-sided. A P-value of 0.05 was taken to
be significant. All analyses were performed using the SPSS
statistical package, version 12.0.1 for Windows.
RESULTS
Baseline characteristics of study subjects
Fifty women were enrolled in the current study, including 25
BRCA1 mutation carriers and 25 non-carrier controls. BRCA1
mutation carriers and controls were similar with respect to current
age, age at menarche, age at first birth, body mass index, and
oral contraceptive use (Table 1). The number of postmenopausal
women was slightly higher among carrier women (15 vs 8,
P¼0.05), and a higher proportion of carriers were current users of
hormone replacement therapy (16.0 vs 0% in carriers and non-
carriers, respectively; P¼0.04). Smoking status, energy intake per
day, alcohol consumption, and the total hours of physical activity
per week were similar for carriers and non-carriers (Table 1).
Comet assay
Table 2 summarises the tail moments in the BRCA1 mutation
carriers and the non-carrier controls at baseline (before irradiation
or 0Gy), immediately following 2Gy of g-irradiation (no recovery
time), and 1h following 2Gy of g-irradiation. As shown in Table 2,
there was no significant difference in the mean tail moment
between the BRCA1 mutation carriers and the controls at baseline
(0Gy), following 2Gy of g-irradiation (no recovery time), and
following 2Gy of g-irradiation with 1h of recovery (P X 0.70 for
all). Adjustment for potential confounders of DNA repair capacity
did not affect the results (see Table 2).
Using the 90th percentile of the non-carrier population, we were
able to classify the study subjects as sensitive or non-sensitive
individuals based on this assay (Figure 1). After 2Gy of
g-irradiation and 1h of recovery, 12.0% of the women with a
BRCA1 mutation (three out of 25) and 8.3% of non-carrier controls
(two out of 24) were judged to be radiosensitive. This suggests no
elevated predisposition to sensitivity among mutation carriers
based on the comet assay (Table 2).
Micronucleus test
No significant differences were observed using the micronucleus
test to quantify DNA repair capacity (Table 3). There was no
significant differences in the mean number of MN per 1000
binucleated cells between the women with a BRCA1 mutation
compared with the non-carrier controls at baseline (before
irradiation or 0Gy), as well as immediately following 2Gy of
g-irradiation (no recovery time) (P¼0.12 and 0.82, respectively).
Adjusting for potential confounders did not affect the results
(Table 3).
Figure 2 illustrates the distribution of the MN per 1000
binucleated cells scores of the entire study population. Using the
90th percentile of the non-carrier controls as the cut-off point for
radiosensitivity (cut-off¼197.69 MN per 1000 binucleated cells),
15% (three out of 20) of the BRCA1 mutation carriers were
radiosensitive compared to 9.5% (two out of 21) of the non-
carriers (data not shown). This difference was not significant
(P¼0.66).
c-H2AX staining
The number of g-H2AX foci per cell were quantified at baseline
(before irradiation or 0Gy), at 30min and at 3h following 2Gy of
g-irradiation (Table 3). There were no significant differences in the
number of g-H2AX foci per cell between BRCA1 mutation carriers
and non-carriers at any of the three time points (PX0.45 for all)
(Table 4).
Table 1 Principal characteristics of the study participants, by mutation
status
Variable
BRCA1 mutation
carriers (BRCA1
+/ )
N¼25
Non-carriers
(BRCA1
WT)
N¼25 P
a
Age at interview
(years), mean (s.d.)
b
43.56 (9.81) 44.62 (11.19) 0.738
Age at menarche,
mean (s.d.)
12.31 (1.40) 12.36 (1.70) 0.916
Age at first birth,
mean (s.d.)
c
26.50 (5.00) 26.79 (4.80) 0.873
Height (inches),
mean (s.d.)
64.38 (2.52) 64.02 (2.15) 0.589
Weight (pounds),
mean (s.d.)
147.84 (30.46) 154.04 (34.77) 0.506
BMI (kgm
 2), mean
(s.d.)
25.02 (4.70) 26.36 (5.63) 0.367
Menopausal status, n (%)
Premenopausal 10 (40) 17 (68)
Postmenopausal 15 (60) 8 (32) 0.047
Hormone replacement therapy use
d, n (%)
Non-user 21 (84) 25 (100)
User 4 (16) 0 (0) 0.037
Oral contraceptive use
d, n (%)
Non-user 23 (92) 20 (80)
User 2 (8) 5 (20) 0.221
Smoking status
d, n (%)
Non-user 25 (100) 22 (88)
User 0 (0) 3 (12) 0.074
Total alcoholic
drinks per day, mean
(s.d.)
0.73 (1.57) 0.70 (0.69) 0.935
Energy intake
(kcalday
 1), mean
(s.d.)
1730.09 (540.23) 1718.02 (443.41) 0.934
Total hours of
physical activity per
week, mean (s.d.)
19.03 (7.25) 22.60 (5.17) 0.065
aAll P-values are univariate and were derived using the Student’s t-test for continuous
variables and the chi-square test for categorical variables.
bs.d.¼standard deviation.
cAmong parous women.
dCurrent use.
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sThe distribution of the scores using g-H2AX staining and the
90th percentile of the non-carriers using g-H2AX staining are
shown in Figure 3 (cut-off¼62.01). Using this value, the
percentage of sensitive BRCA1 mutation carriers was not
significantly different compared with the non-carriers (10.0%
(two out of 19) vs 6.3% (one out of 16), P¼1.00, respectively) (data
not shown).
DISCUSSION
The aim of the current study was to elucidate a simple, rapid, and
inexpensive biomarker for use in future intervention studies of
high-risk women. We examined the potential for the comet assay,
micronucleus test, and g-H2AX staining to discriminate between
women with and without a BRCA1 mutation. We found no
difference in DNA repair capacity using any of these tests. These
assays were chosen because they are rapid and simple, and they
have successfully been employed to screen for radiation-sensitive
individuals and individuals with cancer-prone syndromes
(Rothfuss et al, 1998; Djuzenova et al, 1999; Kuhne et al, 2004).
As a panel, the three tests measure both the immediate effect of
radiation on DNA breakage, and DNA repair capacity up to 24h
post-irradiation. H2AX is a histone, which within seconds of
damage to double-stranded DNA, becomes phosphorylated to
yield g-H2AX that form foci that flank regions of the double-
stranded DNA breaks (Pilch et al, 2003). One g-H2AX focus has
been shown to be equivalent to one double-strand break
(Sedelnikova et al, 2002) and contain hundreds to thousands of
g-H2AX molecules (Rogakou et al, 1998). g-H2AX nuclear foci are
counted using immunofluorescence. Detection of foci is used to
evaluate the induction of radiation-induced double-stranded DNA
breaks in lymphocytes (Petersen et al, 2001; Fernandez-Capetillo
et al, 2003; Pilch et al, 2003; Rothkamm and Lobrich, 2003; Kuhne
et al, 2004). The alkaline comet assay measures both acute DNA
damage and rate of repair (Olive, 2002) and was measured
immediately post-irradiation and 1h thereafter. The micronucleus
test is a variant of the chromosome aberration assay and measures
the frequency of micronuclei in binucleated cells, as an estimate of
chromosomal breakage (Wojewodzka et al, 1997; Rothfuss et al,
2000; Westphal et al, 2003). Micronucelei were measured before
irradiation and 24h after irradiation. We observed no significant
differences in the mean values of DNA damage before g-irradiation
or following repair, or in the percentage of sensitive individuals,
for any of the three assays employed, when mutation carriers and
non-carriers were compared. This suggests that the comet assay,
micronucleus test and g-H2AX nuclear staining are not capable of
distinguishing between BRCA1 mutation carriers and non-carriers.
Deficient DNA repair may not be a phenotype displayed by
heterozygous BRCA1 mutation carriers; that is, the presence of one
functional allele among mutation carriers may be sufficient to
maintain DNA repair at adequate levels. Alternatively, there may in
fact be a phenotype associated with the BRCA1 heterozygote state,
but this panel of assays is not be capable of discriminating between
women with and without a BRCA1 gene mutation. We chose not to
measure bleomycin-induced chromosome aberrations because
this assay is labour intensive and we hoped to identify a less
costly biomarker. Furthermore, we studied relatively small
numbers of cases and controls (25 of each) and our power was
limited to detecting large effects. We only evaluated DNA repair at
one radiation dose level and at one time period post-irradiation. It
is possible that we would have better discrimination if we were to
study DNA repair efficiency at various doses and over a longer-
time period. However, it should be noted that each of the three
assays was highly sensitive for detecting the effect of radiation per
se; that is, post-irradiation levels of DNA damage were clearly
elevated above baseline.
Kowalska et al (2005) reported that carriers of a BRCA1
mutation had a significantly greater frequency of bleomycin-
induced chromosome breaks then non-carrier relatives. In a recent
publication from the UK, the mean number of chromosomal
aberrations (translocations and breaks) per metaphase cell were
scored at 24h, and 6 days following high-dose irradiation (8Gy).
After 6 days, chromosomal damage was found to be significantly
higher in lymphocytes from heterozygous BRCA1 mutation
carriers compared with normal controls (average number of
aberrations per mitosis was 3.5 for cases and 1.6 for controls,
P¼0.0001) (Kote-Jarai et al, 2006). No difference in aberrations
was detected at 24h post-irradiation. The authors concluded that
lymphocytes heterozygous for BRCA1 demonstrate an impaired
capacity to efficiently repair DNA damage following irradiation
resulting in the continued existence of cells with chromosomal
aberrations. This group also reported differential gene expression
in normal breast fibroblasts after radiation-induced DNA damage
in carriers vs controls (Kote-Jarai et al, 2004). Among the genes
Table 2 Crude and adjusted mean tail moments in study population, stratified by BRCA1 mutation status
Crude mean (7s.e.m.) Adjusted mean
b (7s.e.m.)
Dose (Gy) Time after irradiation (h) BRCA1
+/  BRCA1
WT P
a BRCA1
+/  BRCA1
WT P
a
0 0 2.63 (0.31) 2.80 (0.31) 0.696 2.99 (0.31) 2.74 (0.15) 0.472
2 0 7.99 (0.67) 7.96 (0.66) 0.974 8.37 (0.59) 7.90 (0.32) 0.486
2 1 3.64 (0.44) 3.71 (0.38) 0.907 4.05 (0.41) 3.68 (0.17) 0.396
aThe Student’s t-test used to test for differences in the crude and adjusted means of the tail moments between BRCA1 mutation carriers and non-carriers.
bMultivariate linear
regression included terms for age (years), BMI (kgm
 2), current smoker (yes/no), alcohol intake (total drinks of per day), physical activity (total hours of per week), and total daily
caloric intake (kcal).
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Figure 1 Distribution of radiation-induced mean tail moments in the
entire study population. Shaded boxes represent women who are
BRCA1
WT and the black boxes represent women who are BRCA1
þ/ .
The solid vertical line represents the cutoff point between radiosensitive
and non-sensitive individuals and was based on the 90
th percentile of the
non-carrier population after 2Gy of g-irradiation and one hour of recovery
time (cutoff¼6.39).
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sthat were differentially expressed, included the downregulation of
RAD51, which encodes a protein known to interact with BRCA1
and participates in the repair of DNA double strand breaks
(Welcsh et al, 2000).
Other groups have evaluated mutagen sensitivity in peripheral
blood lymphocytes, fibroblasts, and lymphoblastoid cell lines,
from women with BRCA1 mutations. Results have been conflicting
(reviewed in Speit and Trenz (2004)). Speit et al (2000) reported
that lymphocytes from women carrying a heterozygous BRCA1
mutation show enhanced sensitivity to g-irradiation, as assessed by
the micronucleus test, but not the comet assay (Rothfuss et al,
2000; Speit et al, 2000; Trenz et al, 2002, 2003b). A second group
showed that carriers of a BRCA1 or BRCA2 mutation were similar
to controls with respect to their capacity to rejoin X-ray induced
DNA breaks, assessed by pulsed-field electrophoresis in fibroblasts
and the comet assay in lymphocytes (Nieuwenhuis et al, 2002). In
another study, lymphocytes from BRCA1 and BRCA2 mutation
carriers showed enhanced sensitivity to radiation by measuring
chromatid breaks (Buchholz et al, 2002). In a small study of nine
individuals with germ-line BRCA1 mutations, Baria et al (2001)
found that the micronucleus test (also referred to as the G0
micronucleus test) was useful at discriminating between carriers
and non-carriers. Similarly, Baeyens et al (2002) observed
enhanced radiosensitivity among breast cancer patients with a
BRCA1 or BRCA2 mutation, vs a control group of healthy women,
with the micronucleus test but not the G2 assay (number of
chromatid breaks). It is interesting to note that for the
micronucleus test, radiation was provided at both a low and high
dose rate, and that enhanced sensitivity among women with a
mutation was documented for the low dose rate (78 vs 33% for low
and high dose rate, respectively). Others have suggested that
radiation applied at a low dose rate allows better discrimination
between radiosensitive and non-sensitive individuals (Jones et al,
1995).
Earlier studies employing lymphoblastoid cell lines with BRCA1
(or BRCA2) mutations demonstrated greater sensitivity to the
chromosome damaging effects of g-radiation, and of hydrogen
peroxide, compared to cells from healthy controls (as assessed by
the micronucleus test or the radiation-induced chromatid break
assay) (Foray et al, 1999; Speit et al, 2000). Recently, Trenz et al
(2003a, 2005) demonstrated no difference in mutagen sensitivity
using lymphoblastoid cell lines from women with and without a
heterozygous BRCA1 mutation, thus highlighting the limitations of
using cell lines to evaluate mutagen sensitivity and DNA repair.
Nieuwenhuis et al (2002) found no difference in the capacity of
heterozygous BRCA1 or BRCA2 mutation carriers to rejoin
radiation-induced DNA breaks in fibroblasts; whereas, dermal
fibroblasts from BRCA1 and BRCA2 mutation carriers showed
enhanced radiosensitivity as assessed by the in vitro radiation
clonogenic survival assay (Buchholz et al, 2002).
In the current study, we used three assays to quantify DNA
damage and subsequent repair in peripheral blood lymphocytes
taken from our study population before and following exposure to
g-irradiation. This provided us with a measure of DNA repair
kinetics rather than an assessment of the fidelity of repair. Other
investigators that have chosen to evaluate the fidelity rather than
the speed of DNA double-strand break repair in lymphoblastoid
cell lines have reported mixed results (Baldeyron et al, 2002;
Coupier et al, 2004). Using the host cell end-joining assay,
Baldeyron et al (2002) observed that cell lines heterozygous for
BRCA1 (with truncating mutations) had reduced fidelity of DNA
double-strand break repair by DNA end-joining compared with
the control cell lines; similarly, Coupier et al (2004) reported that
fidelity of end-joining was impaired in four cell lines harbouring
BRCA1 missense mutations. These findings suggest that specific
BRCA1 mutations may affect the efficiency rather than the speed
of DNA repair. The results from the comet assay and g-H2AX
staining illustrate that there was no difference in the repair kinetics
in our study population. Whereas we did not detect any differences
with the MNT, which provides a measure of fidelity.
Depending on the type of DNA lesion, the appropriate repair
pathway will be activated (Hoeijmakers, 2001; Kastan and Bartek,
2004). The BRCA1 protein is involved in double-strand break
repair, but also in other repair pathways, including transcription-
coupled repair, nucleotide-excision repair and mismatch repair
(Trenz et al, 2003b). As both carriers and non-carriers showed
similar sensitivities to radiation-induced damage, perhaps quanti-
fying other forms of damage and subsequent repair (i.e. at the
chromosomal level) may be more effective in discriminating
between carriers and non-carriers.
We did not observe any difference in radiation sensitivity
among our sample of women using the panel of three assays.
Subsequently, they are unlikely to be predictors of breast cancer
susceptibility. At the present time, there is no standard functional
test that can be applied routinely to allow discrimination between
carriers and non-carriers. Even though various studies described
above have detected differences in mutagen sensitivity, they were
often limited by their sample size, choice of study population (i.e.
some included both men and women, cancer patients), and
lymphoblastoid cell lines that may display a different response to
Table 3 Crude and adjusted mean micronucleus frequencies, stratified by BRCA1 mutation carriers and non-carriers
Crude mean (7s.e.m.) Adjusted mean
b (7s.e.m.)
Dose (Gy) Time after irradiation (h) BRCA1
+/  BRCA1
WT P
a BRCA1
+/  BRCA1
WT P
a
0 0 25.06 (3.39) 18.00 (2.89) 0.120 20.89 (3.26) 19.96 (1.81) 0.794
2 0 132.77 (12.39) 128.84 (12.03) 0.821 124.70 (4.69) 139.79 (7.37) 0.114
aThe Student’s t-test used to test for differences in the crude and adjusted means of the tail moments between BRCA1 mutation carriers and non-carriers.
bMultivariate linear
regression included terms for age (years), BMI (kgm
 2), current smoker (yes/no), alcohol intake (total drinks of per day), physical activity (total hours per week), and total daily
caloric intake (kcal).
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Figure 2 Distribution of radiation-induced micronucleus frequencies in
the entire study population. Shaded boxes represent women who are
BRCA1
WT and the black boxes represent women who are BRCA1
þ/ . The
solid vertical line represents the cutoff point between radiosensitive and
non-sensitive individuals and was based on the 90
th percentile of the non-
carrier population after 2Gy of g-irradiation and no recovery time
(cutoff¼197.69).
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sradiation when compared to peripheral blood lymphocytes
(Baeyens et al, 2004). Strengths of our study include the evaluation
of multiple endpoints (before and after exposure to g-irradiation),
a relatively large sample of carriers, the use of controls who were
from a family with a previously identified mutation, and employing
a single technician who was blinded to the mutation status of the
samples. Nontheless, these findings collectively suggest that
perhaps markers of chromosomal damage (i.e. chromosomal
breaks, chromatid breaks) may serve as better biomarkers of risk.
Although there are numerous techniques to assess DNA repair
capacity, there is presently no gold standard (Berwick and Vineis,
2000; Hemminki and Thilly, 2004).
Various cytogenetic end-points, including counting chromoso-
mal aberrations, sister chromatic exchanges and micronuclei have
previously been utilised as biomarkers of cancer susceptibility in
non-carriers (reviewed in Norppa (2004)). Epidemiological evi-
dence supports a predictive value of an elevated frequency of
chromosomal aberrations in peripheral blood lymphocytes
(Hagmar et al, 2004). In the Nordic (Hagmar et al, 1994), Italian
(Bonassi et al, 1995), and Czech (Smerhovsky et al, 2001), cohort
studies, the authors evaluated the association between the
frequency of chromosomal aberrations, sister chromatid exchange
or micronuclei in peripheral blood lymphocytes of individuals and
the subsequent risk of cancer. The reported findings showed an
approximately two-fold increase in the risk of cancer among those
with the highest frequencies of chromosomal aberrations (re-
viewed in Hagmar et al (2004)). No association was found with the
other markers (i.e. sister chromatid exchanges or micronuclei).
Collectively, these studies have demonstrated that chromosomal
aberrations can predict cancer risk in humans in some settings.
The advantages and disadvantages of using DNA repair as a
marker of cancer susceptibility has received considerable attention
(Berwick and Vineis, 2000). Limitations include inter- and intra-
individual variability in the assay, test reliability, and biological
plausibility (reviewed in Berwick and Vineis (2000)). An under-
lying assumption in using these assays is that DNA repair capacity
in peripheral lymphocytes is representative of repair in the breast
tissue. It is possible that repair capacity differs between breast
tissue and lymphocytes; however, BRCA1 is expressed in most
tissues and cell types, especially during the S and G2 phases
(reviewed in Venkitaraman (2002)). It is possible that the dose of
radiation used in the present study may have been too high to
detect a difference. However, others have successfully detected
differences with 4Gymin
 1 (Jones et al, 1995).
CONCLUSION
Based on the functions of the BRCA1 protein in DNA repair and
the prevention of oxidative stress, it has been proposed that there
is potential for the prevention of hereditary breast cancer through
lifestyle modification, including dietary changes that decrease
oxidative DNA damage or enhance DNA damage repair pathways
(Kotsopoulos and Narod, 2005). We did not find any significant
differences in DNA repair capacity in peripheral blood lympho-
cytes between BRCA1 mutation carriers and non-carrier controls
using the three different measures. The comet assay, micronucleus
test, and g-H2AX staining are not substitutes for other cytogenetic
markers (i.e. the frequency of chromosome breaks) as markers of
cancer susceptibility in this high-risk group. The ability of
individual genetic and non–genetic factors to predict DNA repair
capacity requires further evaluation.
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